Immunova

Immunova is a private, clinical-stage biotechnology company pioneering a novel approach to cancer treatment through its Nanolipogel™ drug delivery platform. This platform enables the co-delivery of multiple therapeutic agents directly to the disease site, aiming to enhance efficacy and reduce systemic toxicity. The company is advancing a pipeline of nanoparticle-based therapies, positioning itself in the competitive but high-potential field of targeted oncology. As a pre-revenue entity, its success hinges on clinical validation, strategic partnerships, and securing further funding to advance its programs.

Nanolipogel™ platform: a proprietary nanotechnology for co-delivering combinations of drugs via nanoparticle formulations targeted to the disease microenvironment.

Immunova competes in the targeted drug delivery and combination therapy space, facing competition from companies developing antibody-drug conjugates (ADCs), lipid nanoparticles, polymer-based drug conjugates, and other nanomedicines. Large pharma and numerous biotechs are pursuing similar goals of improving drug targeting and efficacy, making differentiation through compelling clinical data essential.